⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Bristol-Myers Squibb made no net changes to its risk factor count, maintaining 20 unchanged risks while substantively modifying three existing disclosures. The modifications focused on financial leverage concerns, capital allocation flexibility, and human capital management, suggesting the company refined its articulation of risks related to debt management, shareholder returns, and workforce retention rather than identifying entirely new risk categories. These adjustments indicate Bristol-Myers Squibb is emphasizing nuance in previously disclosed risk areas without expanding or contracting its overall risk disclosure scope.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟡 Modified

We have significant indebtedness that could have negative consequences.

high match confidence

Sentence-level differences:

Reworded sentence: "Certain of our acquisitions, including most recently the Mirati, Karuna and RayzeBio acquisitions, increased the amount of our debt resulting in additional interest expense, and we may incur more debt to finance future acquisitions."

Current (2026):

Read full text

Certain of our acquisitions, including most recently the Mirati, Karuna and RayzeBio acquisitions, increased the amount of our debt resulting in additional interest expense, and we may incur more debt to finance future acquisitions. Although we have recently taken measures to reduce our debt, this could reduce our financial flexibility to continue capital investments, develop new products and declare future dividends. For example, following the December 2023 announcements of previous acquisitions, Standard & Poor’s downgraded BMS’s long term-credit rating from A+ to A (with a stable long-term credit outlook).

View prior text (2025)

Our acquisitions of Celgene, MyoKardia, Mirati, Karuna and RayzeBio increased the amount of our debt resulting in additional interest expense, and we may incur more debt to finance future acquisitions. This could reduce our financial flexibility to continue capital investments, develop new products and declare future dividends. For example, following the December 2023 announcements of previous acquisitions, Standard & Poor’s downgraded BMS’s long term-credit rating from A+ to A (with a stable long-term credit outlook).

🟡 Modified There can be no guarantee that we will pay dividends or repurchase stock. 🔒

🟡 Modified Failure to attract and retain a highly qualified workforce or to maintain our workplace culture could affect our ability to successfully develop and commercialize products. 🔒

2 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →